Brief: Galapagos, Gilead Enter Binding Agreement On Ouro Medicines Acquisition
31/03/2026 06:32
March 31 (Reuters) - Gilead Sciences Inc GILD.O: ENTERS BINDING AGREEMENT WITH GILEAD ON OURO MEDICINES ACQUISITION GALAPAGOS AND GILEAD ENTER INTO BINDING AGREEMENT TO COLLABORATE ON ADVANCING FIRST IN CLASS T CELL ENGAGER PROGRAM FOR AUTOIMMUNE DISEASES TO FUND 50% OF $1.675 BILLION UPFRONT AND 50% OF MILESTONE PAYMENTS FOR OURO DEAL MAY SPEND $500 MILLION INDEPENDENTLY, INCLUDING UP TO $150 MILLION FOR SHARE REPURCHASES OR DIVIDENDS Source text: ID:nGNE5kcYXR Further company coverage: GILD.O (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Lakefront Biotherapeutics NV
See all newsBrief: Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
Brief: Lakefront Receives Transparency Notification From Bank Of America
Belgium's Galapagos Q1 revenue falls 91% but returns to profit
Brief: Galapagos, Gilead Enter Binding Agreement On Ouro Medicines Acquisition
Brief: Galapagos Announces Nomination Of Gino Santini To Its Board Of Directors